Since lower U2AF1 expression predicted poorer prognosis, we knocked down U2AF1 in BxPC-3 and AsPC-1 pancreatic cancer cells using shRNA, which significantly reduced both the mRNA and protein levels of U2AF1 (Figure 2D,E), and then measured the expression of CD44V3. This evidence concerns the gene U2AF1 and familial pancreatic carcinoma.